Novartis says revolade shows long-term disease control for chronic/persistent immune thrombocytopenia
ZURICH (Reuters) - Novartis said on Wednesday a long term study of its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients' blood does not clot normally. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Rare Thrombosis, Thrombocytopenia Seen After AstraZeneca COVID - 19 Vaccine
Reports document 16 reactions in young European patients following first dose of ChAdOx1 nCoV - 19 vaccine (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 12, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Infections, Internal Medicine, Emergency Medicine, Nursing, Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A well-respected former profess... Biopharmaceuticals, Personnel Rigel Pharmaceuticals, Tavalisse, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 25, 2017 Category: Pharmaceuticals Source Type: news
FDA Accepts Rigel's New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
SOUTH SAN FRANCISCO, Calif., June 19, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISS... Biopharmaceuticals, FDA Rigel Pharmaceuticals, TAVALISSE, fostamatinib, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2017 Category: Pharmaceuticals Source Type: news
A Newborn With Cutaneous Lesions and Hematochezia A Newborn With Cutaneous Lesions and Hematochezia
Can you identify the underlying cause of this newborn ' s dermal lesion, thrombocytopenia, and rectal bleeding?Medscape Pediatrics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2017 Category: Consumer Health News Tags: Pediatrics Clinical Case Source Type: news
What Causes Anemia?
Discussion
One of the most common problems in pediatrics is anemia. It is defined as “a lower than normal value for the related measurements of hemoglobin, hematocrit, and number of red blood cells”, usually 2 standard deviations below the normal for age. Normal hematological values change with age. For a discussion of which values are used click here.
The most common type of anemia in childhood is iron deficiency which is commonly caused by inadequate stores (e.g. premature infant), inadequate intake (e.g. poor nutrition) or blood loss (e.g. menses). Anemia screening is recommended at age 9-12 months, and for...
Source: PediatricEducation.org - May 15, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
SOUTH SAN FRANCISCO, Calif., April 27, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Tavalisse... Biopharmaceuticals, Oncology Rigel Pharmaceuticals, Tavalisse, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2017 Category: Pharmaceuticals Source Type: news
Rigel Pharmaceuticals submits NDA to FDA for Fostamatinib to treat chronic ITP
Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for an oral investigational drug candidate, Fostamatinib, for the treatment of chronic and persistent immune thrombocytopenia (ITP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 18, 2017 Category: Pharmaceuticals Source Type: news
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
SOUTH SAN FRANCISCO, Calif., April 17, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fosta... Biopharmaceuticals Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 17, 2017 Category: Pharmaceuticals Source Type: news
Presentation of Severe Fever With Thrombocytopenia Syndrome Presentation of Severe Fever With Thrombocytopenia Syndrome
This case details an unusual presentation of encephalopathy in a patient with severe fever with thrombocytopenia syndrome, an emerging infectious disease that has recently been identified in Asia.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news
Eltrombopag Improved Platelet Counts in Thrombocytopenic MDS Patients
The use of the thrombopoietin receptor agonist eltrombopag was clinically effective at raising platelet counts in patients with lower-risk myelodysplastic syndromes with severe thrombocytopenia. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news
Ocular Complications of Congenital Infections
This article summarizes the ocular complications of the 5 infections typically represented by the acronym TORCHES (toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and syphilis), as well as others, including newer pathogens such as the human immunodeficiency, West Nile, and Zika viruses. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - January 31, 2017 Category: Pediatrics Authors: Khazaeni, L. M. Tags: Pediatric Drug Labeling Update Articles Source Type: news
[Report] IgG antibodies to dengue enhanced for Fc γRIIIA binding determine disease severity
Dengue virus (DENV) infection in the presence of reactive, non-neutralizing immunoglobulin G (IgG) (RNNIg) is the greatest risk factor for dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Progression to DHF/DSS is attributed to antibody-dependent enhancement (ADE); however, because only a fraction of infections occurring in the presence of RNNIg advance to DHF/DSS, the presence of RNNIg alone cannot account for disease severity. We discovered that DHF/DSS patients respond to infection by producing IgGs with enhanced affinity for the activating Fc receptor FcγRIIIA due to afucosylated Fc glycans and IgG1 subc...
Source: ScienceNOW - January 26, 2017 Category: Science Authors: Taia T. Wang Source Type: news
Severe Thrombocytopenia in a Child With Typhoid Fever Severe Thrombocytopenia in a Child With Typhoid Fever
How should thrombocytopenia in typhoid fever be managed? The successful outcome of this occurrence in a young traveler provides some guidance.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2017 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016
Sub-Analysis From Phase 3 TOWER Study Compares Health-Related Quality of Life of BLINCYTO® (Blinatumomab) to Standard of Care Chemotherapy
Analysis of Phase 3 Data Evaluates Cost-Effectiveness of KYPROLIS® (Carfilzomib) in Combination With Dexamethasone for Relapsed Multiple Myeloma Patients
Long-Term Data Provide Insights on Safety and Efficacy of Nplate® (Romiplostim) in Children With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Nov. 30, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), ...
Source: Amgen News Release - November 30, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
